[Federal Register Volume 67, Number 217 (Friday, November 8, 2002)]
[Notices]
[Pages 68144-68145]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-28536]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by agencies of the U.S.

[[Page 68145]]

Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

New Gene Expressed in Prostate Cancer and Methods of Use

    TK Bera, C Wolfgang, I Pastan (NCI), B Lee, J Vincent;
    DHHS Reference No. E-005-2002 filed Nov. 14, 2001;
    Licensing Contact: Jonathan Dixon; 301/435-5559; [email protected].
    A new polypeptide is described in this invention that is 
specifically detected in the cells of the prostate. This polypeptide 
has been termed Novel Gene Expressed In Prostate (NGEP). There are 
potential claims to the NGEP gene, polynucleotides encoding NGEP, 
antibodies to NGEP, methods for using an NGEP polypeptide, 
polynucleotide, or antibody, and pharmaceutical compositions containing 
any of the above NGEP-related molecules. This invention might be useful 
in prostate cancer diagnostics, such as an assay to detect prostate 
cancer, or as a therapeutic directed towards prostate cancer.

Use of Interferon-Inducible 2',5'-Oligoadenylate-Dependent RNase in the 
Diagnosis, Prognosis, and Treatment of Prostate Cancer

    J. Carpten (NHGRI), J. Trent (NHGRI), J. Smith, P. Walsh, W. 
Isaacs, D. Stephan, and N. Nupponen (NHGRI);
    PCT Application PCT/US02/19516 (DHHS Ref. E-196-01/1), claiming 
priority to a U.S. Provisional Patent Application filed on June 20, 
2001;
    Licensing Contact: Brenda Hefti; 301/435-4632; [email protected].
    This invention pertains to the use of interferon-inducible 2',5'-
oligoadenlyate-dependent RNase L in the diagnosis, prognosis and 
treatment of cancer, particularly prostate cancer. The inventors have 
identified a potential prostate cancer susceptibility locus, which has 
been designated HPC1 due to its putative link to hereditary prostate 
cancer. HPC1 may lead to an early, sensitive and accurate method for 
detecting cancer or a predisposition to cancer, especially prostate 
cancer, in a mammal. In addition, such claimed methods can be used to 
monitor onset and progression of cancer, as well as a patient's 
response to a particular treatment.

Signal Transduction Inhibitor Compounds in Clinical Trials as Cancer 
Therapeutics

    Elise C. Kohn, Lance A. Liotta, Christian C. Felder (NCI);
    U.S. Patent 5,359,078 issued October 25, 1994;
    U.S. Patent 5,482,954 issued January 9, 1996;
    U.S. Patent 5,498,620 issued March 12, 1996;
    U.S. Patent 5,705,514 issued January 6, 1998;
    U.S. Patent 5,880,129 issued March 9, 1999;
    Licensing Contact: Brenda Hefti; 301/435-4632; [email protected].
    The above issued patents relate to azole, diazole, and triazole 
compounds that appear to inhibit signal transduction and inhibit 
invasion and metastasis of malignant solid tumors. A number of these 
compounds are in phase I, II and III clinical trials for specific 
indications, and might be useful in other indications as well.
    These issued patents claim a number of compositions of matter, 
pharmaceutical compositions of said compounds, and methods of using 
said compounds.

    Dated: November 4, 2002.
Jack Spiegel,
Director, Division of Technology, Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 02-28536 Filed 11-7-02; 8:45 am]
BILLING CODE 4140-01-P